{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-134389","form_type":"8-K","ticker":"NTRA","cik":"0001604821","company_name":"Natera, Inc.","filed_at":"2021-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.289292+00:00","generated_at":"2026-06-28T13:01:22.328317+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Natera Q3 revenue $158.1M (+61% YoY), net loss $151.3M; raises FY2021 revenue guidance","bullets":["Revenue $158.1M (+61.1% YoY); product revenue $150.7M (+61.5%); tests processed 407,300 (+55.4%).","Net loss $151.3M (EPS -$1.63) vs loss $58.3M (-$0.72) in Q3 2020; operating loss $150.2M.","Raises 2021 revenue guidance to $615-625M from prior; expects gross margin 49-52%; SG&A $500-520M; R&D $240-260M.","Cash $1.0B; total debt $330.1M ($287.5M convertible notes principal; $50M credit line).","Launched Prospera Kidney/Heart/Lung; exclusive license from Aarhus University for colorectal cancer screening biobank."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-134389","json":"https://secwatch.observer/filing/0001104659-21-134389.json","markdown":"https://secwatch.observer/filing/0001104659-21-134389.md","text":"https://secwatch.observer/filing/0001104659-21-134389.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604821/000110465921134389/0001104659-21-134389-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604821/000110465921134389/tm2131935d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T13:01:22.328317+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}